60 related articles for article (PubMed ID: 3024600)
1. A new vasodilator 3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine (KC-404) has a dual mechanism of action on platelet aggregation.
Ohashi M; Ohkubo H; Kito J; Nishino K
Arch Int Pharmacodyn Ther; 1986 Oct; 283(2):321-34. PubMed ID: 3024600
[TBL] [Abstract][Full Text] [Related]
2. Potentiating effect of 3-isobutyryl-2-isopropylpyrazolo-[1,5a]-pyridine (KC-404), a new cerebral vasodilator with anti-platelet activity, on prostacyclin-induced increase of cyclic AMP content in platelets of rat.
Hisayama T; Takayanagi I; Goromaru N; Okamoto Y
Gen Pharmacol; 1989; 20(2):183-6. PubMed ID: 2541044
[TBL] [Abstract][Full Text] [Related]
3. Influence of selective thromboxane synthetase blocker CGS-13080 on thromboxane and prostacyclin biosynthesis in whole blood: evidence for synthesis of prostacyclin by leukocytes from platelet-derived endoperoxides.
Mehta J; Mehta P; Lawson DL; Ostrowski N; Brigmon L
J Lab Clin Med; 1985 Sep; 106(3):246-52. PubMed ID: 3928780
[TBL] [Abstract][Full Text] [Related]
4. Mode of cerebral vasodilating action of KC-404 in isolated canine basilar artery.
Ohashi M; Kito J; Nishino K
Arch Int Pharmacodyn Ther; 1986 Apr; 280(2):216-29. PubMed ID: 3087305
[TBL] [Abstract][Full Text] [Related]
5. Effect of 1-methyl-2-mercapto-5-(3-pyridyl)-imidazole (KC-6141) on rabbit platelet aggregation in vitro and rat platelet retention.
Umetsu T; Kato T
Thromb Haemost; 1978 Feb; 39(1):167-76. PubMed ID: 580491
[TBL] [Abstract][Full Text] [Related]
6. Effects of CI-930, a novel phosphodiesterase III inhibitor, on platelet aggregation and arachidonic acid metabolism.
Chen XS; Zeng HW; Jiang YY; Wan WQ; Long K
Zhongguo Yao Li Xue Bao; 1990 Jul; 11(4):338-43. PubMed ID: 1966575
[TBL] [Abstract][Full Text] [Related]
7. [Studies on the inhibitory effect of etafenone hydrochloride on platelet aggregation].
Ujiie A; Komatsu H; Kubota T; Hamano S; Naito J
Nihon Yakurigaku Zasshi; 1983 Jun; 81(6):493-8. PubMed ID: 6618341
[TBL] [Abstract][Full Text] [Related]
8. Thromboxane-mediated activation of platelets and enhancement of platelet uptake onto collagen-coated glass or deendothelialized rabbit aorta. Comparative effects of a thromboxane antagonist (EPO45) and a thromboxane synthetase inhibitor (dazoxiben).
Menys VC; Davies JA
Lab Invest; 1984 Feb; 50(2):184-9. PubMed ID: 6546403
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of antiplatelet activity of PC-09, a newly synthesized pyridazinone derivative.
Cherng SC; Huang WH; Shiau CY; Lee AR; Chou TC
Eur J Pharmacol; 2006 Feb; 532(1-2):32-7. PubMed ID: 16457809
[TBL] [Abstract][Full Text] [Related]
10. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP.
Maurice DH; Haslam RJ
Mol Pharmacol; 1990 May; 37(5):671-81. PubMed ID: 2160060
[TBL] [Abstract][Full Text] [Related]
11. Mepacrine-induced elevation of cyclic GMP levels and acceleration of reversal of ADP-induced aggregation in washed rabbit platelets.
Matsuoka I; Suzuki T
J Cyclic Nucleotide Protein Phosphor Res; 1983; 9(4-5):341-53. PubMed ID: 6147364
[TBL] [Abstract][Full Text] [Related]
12. Effect of a single Ditazole dose on platelet aggregation and prostaglandin formation.
Prisco D; Bartoletti A; Lombardi A
Int J Clin Pharmacol Res; 1984; 4(2):129-36. PubMed ID: 6147319
[TBL] [Abstract][Full Text] [Related]
13. The effect of cooling on in vitro vascular prostacyclin and platelet thromboxane A2 synthesis: relevance to cold-induced pathology.
Jeremy JY; Mikhailidis DP; Hutton RA; Dandona P
Microcirc Endothelium Lymphatics; 1988 Feb; 4(1):3-20. PubMed ID: 2837626
[TBL] [Abstract][Full Text] [Related]
14. Effects of the new antiplatelet agent 2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo[1,5-a]pyridine on platelet aggregation and thrombosis in experimental animals.
Momo K; Someya K; Tachiiri T; Mitsuoka Y; Nakamura K; Imai S; Ino T; Ohkubo H
Arzneimittelforschung; 1992 Jan; 42(1):32-9. PubMed ID: 1586377
[TBL] [Abstract][Full Text] [Related]
15. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--I. Biochemical profile in vitro.
De Clerck F; Beetens J; de Chaffoy de Courcelles D; Freyne E; Janssen PA
Thromb Haemost; 1989 Feb; 61(1):35-42. PubMed ID: 2546278
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelium and platelet preparations for the prediction of xenobiotic effects on the vascular system.
Togna G; Togna AR; Caprino L
Xenobiotica; 1985; 15(8-9):661-4. PubMed ID: 3934852
[TBL] [Abstract][Full Text] [Related]
17. Novel thienylacylhydrazone derivatives inhibit platelet aggregation through cyclic nucleotides modulation and thromboxane A2 synthesis inhibition.
Brito FC; Kummerle AE; Lugnier C; Fraga CA; Barreiro EJ; Miranda AL
Eur J Pharmacol; 2010 Jul; 638(1-3):5-12. PubMed ID: 20412790
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological properties of the new stable prostacyclin analogue 3-Oxa-methano-prostaglandin I.
Yamamoto T; Satoh K; Nishimura T; Horikawa N; Mine T; Hirohashi T; Hara Y
Arzneimittelforschung; 1994 Apr; 44(4):483-90. PubMed ID: 8011001
[TBL] [Abstract][Full Text] [Related]
19. 7-Bromo-1,5-dihydro-3,6-dimethylimidazo[2,1-b]quinazolin-2(3H)- one (Ro 15-2041), a potent antithrombotic agent that selectively inhibits platelet cyclic AMP-phosphodiesterase.
Muggli R; Tschopp TB; Mittelholzer E; Baumgartner HR
J Pharmacol Exp Ther; 1985 Oct; 235(1):212-9. PubMed ID: 2995647
[TBL] [Abstract][Full Text] [Related]
20. Platelet hyperactivity in acute myocardial infarction in man--effects of prostacyclin.
Mueller HS; Rao PS; Greenberg MA; Buttrick PM; Sussman II; Levite HA; Grose RM; Perez-Davila V; Strain JE; Spaet TH
Herz; 1986 Apr; 11(2):116-26. PubMed ID: 2939012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
